FAP still more question to be answered: A review-based analysis
Loading...
Supplementary material
Other Title
Authors
Vyas, Madhusudan
Glassunburry, A.
Glassunburry, A.
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2023-08-28
Supervisors
Type
Conference Contribution - Paper in Published Proceedings
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
fibroblast activation protein (FAP)
oncology imaging
oncology imaging
ANZSRC Field of Research Code (2020)
Citation
Vyas, Madhusudan., & Glassunburry, Angus. (2023). FAP still more question to be answered: A review-based analysis. In Journal of Nuclear Medicine (Ed.), SNMMI-2023 , Vol. 64 (pp. T55). doi:2159-662X https://jnm.snmjournals.org/content/64/supplement_1/T55
Abstract
Over ninety percent of epithelial malignancies have elevated levels of fibroblast activation protein (FAP), a type II transmembrane serine protease that is closely associated with tumour invasion, metastasis, and prognosis. Using FAP as a target, different FAP inhibitors (FAPIs) have been developed; the majority of these FAPIs have nanomolar levels of FAP affinity and high selectivity, and they are used for positron emission tomography (PET) imaging of diverse cancers. FAPIs are projected to be the new molecule of the century with greater imaging effects than 18F-FDG in a number of diseases, such as gastrointestinal tumours, liver tumours, breast tumours, and nasopharyngeal carcinoma, based on current research. FAPIs are a complementing molecular imaging method to 18F-FDG. Current paper present the review of currebntly published litreature in terms of FAPI and its clinical role in oncology.
Publisher
Society of Nuclear Medicine and Molecular Imaging
Permanent link
Link to ePress publication
DOI
Copyright holder
Society of Nuclear Medicine and Molecular Imaging
Copyright notice
Attribution-NonCommercial 4.0 International